8 June 2012
TiGenix obtains national reimbursement in the Netherlands for breakthrough cartilage therapy ChondroCelect®
Leuven (BELGIUM) – June 8, 2012 – TiGenix (NYSE Euronext: TIG) announced today that its innovative cartilage repair therapy ChondroCelect® has obtained national reimbursement in the Netherlands. The Dutch National Health Authority (NZa) has formally announced that ChondroCelect® is to receive national reimbursement retroactively per January 1, 2012. Previously ChondroCelect® was made available in the Netherlands under a risk-sharing scheme.
“We are delighted with the decision of the NZa to reimburse ChondroCelect®, and look forward to working with Dutch orthopedic centers of excellence and health insurers to routinely make this breakthrough therapy available to the right patients in the Netherlands,” said Eduardo Bravo, CEO of TiGenix. “Dutch clinicians and scientists have been instrumental in ChondroCelect’s development and four Cartilage Expert Centers in the Netherlands have already gained extensive experience with the procedure. After having obtained national reimbursement in Belgium last year, this constitutes another major step in improving patient access to this innovative therapy. We remain optimistic that we can obtain
national reimbursement in other European countries later this year.”